Cellestia is a biopharmaceutical company developing innovative first-in-class anti-cancer drugs. Our clinical stage lead compound CB-103 is a selective oncogene transcription factor inhibitor for treatment of currently untreatable cancers driven by oncogenic activation of NOTCH.

Cooperation possibilities

R&D, co-development, licensing

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2014
  • Number of employees in Switzerland
    1-9
Key business